INVESTMENT STYLE:

Primarily focuses on investment in at least 80% of its net assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India.

INVESTMENT OBJECTIVE:

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.

DATE OF ALLOTMENT:

December 28,2015

FUND MANAGER(S)

Meeta Shetty (Managing Since 09-Mar-21 and overall experience of 17 years) (Managed in the past from 09-Nov-2018 to 08-March- 2021 as Lead Fund Manager)

ASSISTANT FUND MANAGER:

Rajat Srivastava (Managing Since 16-Sep-24 and overall experience of 10 years)

BENCHMARK:

Nifty Pharma TRI

NAV (in Rs.)

Direct - IDCW	35.1102
Direct - Growth	35.1102
Reg - IDCW	30.4821
Reg - Growth	30.4821
FUND SIZE
Rs. 1213.92 (Rs. in Cr.)
MONTHLY AVERAGE AUM
Rs. 1190.93 (Rs. in Cr.)
TURN OVER
Portfolio Turnover (Equity component only)	9.47%
EXPENSE RATIO**
Direct	0.69
Regular	2.14
**Note: The rates specified are actual month end expenses charged as on Nov 30, 2024. The above ratio includes the Service tax on Investment Management Fees. The above ratio excludes, borrowing cost, wherever applicable.

VOLATILITY MEASURES^	FUND	BENCHMARK
Std. Dev (Annualised)	15.14	16.23
Sharpe Ratio	0.85	0.72
Portfolio Beta	0.89	NA
R Squared	0.97	NA
Treynor	1.21	NA
Jenson	0.21	NA
^Risk-free rate based on the FBIL Overnight MIBOR rate of 6.76% as on Nov 29, 2024 For calculation methodology

MINIMUM INVESTMENT/
MULTIPLES FOR NEW INVESTMENT:

Rs. 5,000/- and in multiples of Re. 1/- thereafter.

ADDITIONAL INVESTMENT/
MULTIPLES FOR EXISTING INVESTORS:

Rs. 1,000/- and multiples of Re. 1/- thereafter.

LOAD STRUCTURE:

ENTRY LOAD	Not Applicable
EXIT LOAD	0.25% of NAV if redeemed/switched out before 30 days from the date of allotment.

Please refer to our Tata Mutual Fund website for fundamental changes, wherever applicable